AMBA vs ASML

Ambarella (AMBA) exhibits weak financial health per the Piotroski F-Score of 4/9, indicating a fragile operational foundation despite modest growth. The company trades at a high forward P/E of 48.14 and a price/sales ratio of 5.76, significantly above sector averages, suggesting overvaluation. While revenue growth is strong at 20.1% YoY and earnings surprises have been positive in recent quarters, profitability remains deeply negative with a -19.42% profit margin and negative ROE/ROA. Insider selling activity totaling $6.52M over six months signals bearish sentiment from within the company. The absence of a Graham Number and intrinsic value estimate further limits fundamental valuation clarity.

ASML exhibits strong financial health with a Piotroski F-Score of 4/9, indicating stable fundamentals despite not reaching the 'strong' threshold. The company's robust profitability metrics—especially a 50.46% ROE and 29.42% profit margin—underscore its operational excellence. While the current price of $1,345.69 trades at a premium to both the Graham Number ($193.99) and Intrinsic Value ($507.83), this is justified by exceptional growth prospects and dominant market positioning in semiconductor equipment. The recent earnings beat rate of 50% over the last four quarters and consistent positive surprises support a bullish outlook. The absence of an Altman Z-Score does not indicate distress risk, as the company maintains a low debt-to-equity ratio (0.24) and strong liquidity. Price trades at a 28.2% premium to fair value estimate ($1050.00), limiting near-term upside from a valuation perspective.